KYMR in the 13F filings
Kymera Therapeutics Inc · CUSIP 501575104
- Quarter end
- 31 Dec 2025
- the date the book describes
- Filed
- 27 Oct 2026
- latest of these filings; the earliest 22 Jan 2026
- Managers listing it
- 25
- at least, of 95 tracked, among listed positions
- Comparable managers
- 92
- filed both Q3 2025 and Q4 2025; 6 listed it in both
- Shares listed
- 24,755,413
- combined, among listed positions
- Reported value
- $1.9bn
- combined, at the quarter end
Among the 92 comparable managers: 15 buyers (opened or added shares) and 12 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was +3,713,220.
Managers listing KYMR in Q4 2025
25 of 25 holders
Largest increases and reductions, by shares
Increases
- Fidelity (FMR LLC)existing position · 8,928,574 shares now+3,048,963
- T. Rowe Price Associates Incexisting position · 6,159,335 shares now+1,061,957
- AllianceBernstein LPexisting position · 952,065 shares now+903,296
- Capital Research Global Investorsexisting position · 1,560,791 shares now+298,609
- Citadel Advisors LLCexisting position · 159,865 shares now+118,042
Reductions
- Wellington Management Group LLPexisting position · 4,412,933 shares now-782,758
- Marshall Wace LLPexisting position · 38,022 shares now-321,054
- Squarepoint Ops LLCexisting position · 159,426 shares now-191,820
- Two Sigma Investments LPexisting position · 265,532 shares now-164,443
- MFS Investment Managementexisting position · 289,404 shares now-145,610
New positions and exits
New (5)
Exited (2)
- Schonfeld Strategic Advisors LLCwas $2.3m
- Hudson Bay Capital Management LPwas $1.3m
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q3 2020 | 2 | $8.3m | n.a. | n.a. |
| Q4 2020 | 1 | $11m | n.a. | n.a. |
| Q2 2021 | 1 | $1.8m | n.a. | n.a. |
| Q3 2021 | 1 | $7.6m | n.a. | n.a. |
| Q4 2021 | 1 | $171m | n.a. | n.a. |
| Q1 2022 | 2 | $30m | n.a. | n.a. |
| Q2 2022 | 1 | $2.0m | n.a. | n.a. |
| Q3 2022 | 1 | $2.2m | n.a. | n.a. |
| Q4 2022 | 3 | $226m | n.a. | n.a. |
| Q1 2023 | 3 | $268m | n.a. | n.a. |
| Q2 2023 | 1 | $2.5m | n.a. | n.a. |
| Q3 2023 | 1 | $1.4m | n.a. | n.a. |
| Q4 2023 | 3 | $150m | 2 | 1 |
| Q1 2024 | 6 | $496m | 4 | 2 |
| Q2 2024 | 4 | $343m | 3 | 1 |
| Q3 2024 | 5 | $582m | 3 | 2 |
| Q4 2024 | 6 | $536m | 5 | 1 |
| Q1 2025 | 4 | $372m | 2 | 3 |
| Q2 2025 | 5 | $615m | 3 | 2 |
| Q3 2025 | 6 | $737m | 2 | 3 |
| Q4 2025 | 7 | $1.7bn | 15 | 12 |
| Q1 2026 | 8 | $2.1bn | 12 | 15 |
| Q2 2026 | 8 | $3.0bn | 12 | 13 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
KYMR and GILD →KYMR and AMGN →KYMR and ARGX →Choose a stock to compare with KYMR →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own KYMR, latest filings →Back to the 13F Explorer →